3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
45
Lymphoma, Non-Hodgkin
15
Lymphoma
15
Leukemia
14
Leukemia, B-Cell
13
Lymphoma, Follicular
11
Recurrence
9
Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, Mantle-Cell
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Burkitt Lymphoma
5
Lymphoma, B-Cell
4
Bronchiolitis Obliterans Syndrome
4
Waldenstrom Macroglobulinemia
3
Lymphoma, B-Cell, Marginal Zone
3
Hodgkin Disease
2
Hematologic Neoplasms
2
Thrombocytopenia
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Oncology Patients Receiving Chemotherapy
1
Melanoma
1
Lymphocytosis
1
Lymphadenopathy
1
Leukemia, Prolymphocytic
1
Leukemia, Lymphoid
1
Fever
1
Fatigue
1
Disease
1
Interventions
fludarabine
3
Cyclophosphamide
3
thymoglobulin
1
prednylidene
1
ofatumumab
1
deltacortene
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Mitoxantrone
1
Melphalan
1
Immunoglobulins, Intravenous
1
Etoposide
1
Cytarabine
1
Carmustine
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Autoimmune Diseases of the Nervous System
×
ofatumumab
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled